Janpix - About the company
Janpix is a deadpooled company based in Cambridge (United States), founded in 2015. It operates as a Developer of small molecules for treating cancer. Janpix has raised $29M in funding from Medicxi. The company has 312 active competitors, including 112 funded and 62 that have exited. Its top competitors include companies like Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics.
Company Details
Janpix is developing small molecules targeting Signal Transducer and Activator of Transcription (STAT) proteins (cytosolic proteins) for treating cancer. The pipeline products are in the preclinical development phase which is used to treat cancers like medulloblastoma, breast, leukemia, and others.
- Website
- janpixbio.com
- Email ID
- *****@janpixbio.com
- Phone Number
- +1 **********
- Registered Address
- C/o Medicxi, 25 Great Pulteney Street, London, England, W1F 9LT
Key Metrics
Founded Year
2015
Location
Cambridge, United States
Stage
Deadpooled
Total Funding
$29M in 3 rounds
Latest Funding Round
Investors
Ranked
211th among 312 active competitors
Similar Companies
Legal entities associated with Janpix
Janpix is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Janpix Ltd. CIN: 08709519 , United States, Active | Mar 29, 2017 | - | - | - |
Sign up to download Janpix's company profile
Janpix's funding and investors
Janpix has raised a total funding of $29M over 3 rounds. Its latest funding round was a Series B round on Oct 07, 2020 for $*****. 1 investor participated in its latest round. Janpix has 1 institutional investor.
Here is the list of recent funding rounds of Janpix:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 07, 2020 | 5766228 | Series B | 1966970 | 6234407 | 9531558 | 7098034 |
Oct 11, 2017 | 7311959 | Series A | 2602540 | 1802247 | 7655586 |
Access funding benchmarks and valuations. Sign up today!View details of Janpix's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Janpix's Competitors and alternates
Top competitors of Janpix include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Janpix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
2nd | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
3rd | _1556184640480.png?devicePixelRatio=2&height=30&width=30){kind=logo} TScan Therapeutics 1995, Boston (United States), Public | Developer of T cell therapies to harness the immune system against cancer | $180M | 70/100 | |
4th | _1548143983431.png?devicePixelRatio=2&height=30&width=30){kind=logo} Beijing Jiakesi drug development 2015, Beijing (China), Public | Developer of small molecule based therapeutics for cancer treatment | $55M | 67/100 | |
5th | Lyell Immunopharma 2018, San Francisco (United States), Public | Developer of CAR- T therapy for cancer treatment | $493M | 63/100 | |
6th | ABL Bio 2016, Seongnam-si (South Korea), Public | Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 63/100 | |
7th | Cumulus Oncology 2017, Edinburgh (United Kingdom), Seed | Developer of therapies for treating cancers | $19.2M | 61/100 | |
8th |  Black Diamond Therapeutics 2017, Cambridge (United States), Public | Developing MasterKey therapies to defeat cancer resistance and improve patient lives | $207M | 61/100 | |
9th | _1568982092325.png?devicePixelRatio=2&height=30&width=30){kind=logo} Boundless Bio 2018, San Diego (United States), Public | Developer of therapeutics for cancer by targeting ecDNA | $252M | 61/100 | |
10th | FoRx Therapeutics 2019, Basel (Switzerland), Series A | Developer of compounds for treating cancer | $60.8M | 60/100 | |
211th |  Janpix 2015, Cambridge (United States), Deadpooled | Developer of small molecules for treating cancer | $29M | 25/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Janpix's competitors? Click here to see the top ones
Janpix's Investments and acquisitions
Janpix has made no investments or acquisitions yet.
Reports related to Janpix
Here is the latest report on Janpix's sector:
News related to Janpix
•
Medicxi’s $10 Million Series B Investment Into JanpixGlobal Legal Chronicle•Oct 21, 2020•Goodwin, medicxi, Janpix
•
Janpix Announces $10 Million Series B Financing to Advance STAT Protein Degrader PipelinePipelinereview•Oct 07, 2020•Janpix, Medicxi
•
•
•
New Biotech Startup to Use $19M in Funding to Advance Dual Cancer TherapiesDrug Discovery & Development•Oct 16, 2017•Janpix, Medicxi
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Janpix
Explore our recently published companies
- Global Food Horizon - Pakistan based, Public company
- Conscientisation - Unfunded company
- Ormond - Ormond Beach based, Unfunded company
- Centralize - Buenos Aires based, 2025 founded, Unfunded company
- TeXef - 2025 founded, Unfunded company
- Frame Bio - Santa Fe based, Unfunded company
